Vaderis Therapeutics announced on Aug. 11 that it has secured $152 million in a series B funding round to support the launch of a Phase 3 clinical trial for its investigational therapy, engasertib, targeting hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease.
The Swiss biotechnology company said the financing round was oversubscribed and coincided with the initiation of the HEROIC study, which will test oral selective allosteric AKT1/2 inhibitor engasertib in patients with HHT. The Phase 3 trial is expected to enroll participants across North America, South America, and Europe.
Hereditary hemorrhagic telangiectasia is an inherited disorder characterized by abnormal connections between arteries and veins known as arteriovenous malformations. These can cause frequent nosebleeds, shortness of breath, seizures, iron deficiency anemia, and overall reduced quality of life.
Vaderis said it aims for engasertib to become the first approved treatment for HHT. The drug targets AKT, a serine kinase involved in vascular growth and overgrowth. According to data published in The New England Journal of Medicine in November 2025, cited by Vaderis, engasertib showed improvements across multiple measures of HHT in patients.
The company reported that proceeds from the fundraising will support operations through regulatory submissions and potential approval by the U.S. Food and Drug Administration. The series B was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX with participation from new investors Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital as well as existing investors Medicxi and Droia.
Vaderis emerged from stealth mode in 2022 after acquiring once-daily engasertib from Almac Discovery in 2020.
